CY2010016I2 - Αντισωματα σε μοριο προσδεσης της οστεοπροτεγερινης (opgl) - Google Patents
Αντισωματα σε μοριο προσδεσης της οστεοπροτεγερινης (opgl)Info
- Publication number
- CY2010016I2 CY2010016I2 CY2010016C CY2010016C CY2010016I2 CY 2010016 I2 CY2010016 I2 CY 2010016I2 CY 2010016 C CY2010016 C CY 2010016C CY 2010016 C CY2010016 C CY 2010016C CY 2010016 I2 CY2010016 I2 CY 2010016I2
- Authority
- CY
- Cyprus
- Prior art keywords
- osteopretegerin
- linding
- opgl
- antibodies
- molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30117201P | 2001-06-26 | 2001-06-26 | |
| PCT/US2002/020181 WO2003002713A2 (en) | 2001-06-26 | 2002-06-25 | Antibodies to opgl |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CY2010016I1 CY2010016I1 (el) | 2012-01-25 |
| CY2010016I2 true CY2010016I2 (el) | 2012-01-25 |
Family
ID=23162250
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100637T CY1110196T1 (el) | 2001-06-26 | 2010-07-08 | Αντισωματα σε μοριο προσδεσης της οστεοπροτεγερινης (opgl) |
| CY2010016C CY2010016I2 (el) | 2001-06-26 | 2010-11-24 | Αντισωματα σε μοριο προσδεσης της οστεοπροτεγερινης (opgl) |
| CY181100655T CY1120656T1 (el) | 2001-06-26 | 2018-06-26 | Αντισωματα ως προς opgl |
| CY181100747T CY1120658T1 (el) | 2001-06-26 | 2018-07-17 | Αντισωματα ως προς opgl |
| CY20191100079T CY1121151T1 (el) | 2001-06-26 | 2019-01-21 | Αντισωματα ως προς opgl |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100637T CY1110196T1 (el) | 2001-06-26 | 2010-07-08 | Αντισωματα σε μοριο προσδεσης της οστεοπροτεγερινης (opgl) |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY181100655T CY1120656T1 (el) | 2001-06-26 | 2018-06-26 | Αντισωματα ως προς opgl |
| CY181100747T CY1120658T1 (el) | 2001-06-26 | 2018-07-17 | Αντισωματα ως προς opgl |
| CY20191100079T CY1121151T1 (el) | 2001-06-26 | 2019-01-21 | Αντισωματα ως προς opgl |
Country Status (33)
| Country | Link |
|---|---|
| US (8) | US7364736B2 (el) |
| EP (5) | EP2295081B1 (el) |
| JP (13) | JP4212470B2 (el) |
| KR (2) | KR101038585B1 (el) |
| CN (2) | CN1547486A (el) |
| AR (1) | AR034637A1 (el) |
| AT (1) | ATE464068T1 (el) |
| AU (2) | AU2002320157C1 (el) |
| BR (1) | BRPI0210579B8 (el) |
| CA (1) | CA2451955C (el) |
| CY (5) | CY1110196T1 (el) |
| DE (2) | DE60235989D1 (el) |
| DK (4) | DK1409016T4 (el) |
| EA (1) | EA021242B9 (el) |
| ES (5) | ES2674888T3 (el) |
| FR (1) | FR10C0050I2 (el) |
| IL (3) | IL159512A0 (el) |
| LU (1) | LU91757I2 (el) |
| ME (2) | MEP32608A (el) |
| MX (1) | MXPA04000134A (el) |
| MY (1) | MY143582A (el) |
| NO (5) | NO345566B1 (el) |
| NZ (4) | NZ616594A (el) |
| PH (2) | PH12012502439A1 (el) |
| PL (1) | PL222211B1 (el) |
| PT (4) | PT2295081T (el) |
| RS (1) | RS54274B1 (el) |
| SG (3) | SG2011076551A (el) |
| TR (3) | TR201900581T4 (el) |
| TW (2) | TWI326285B (el) |
| WO (1) | WO2003002713A2 (el) |
| YU (1) | YU103003A (el) |
| ZA (1) | ZA200400521B (el) |
Families Citing this family (210)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| EP2003203A1 (en) | 1996-12-23 | 2008-12-17 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily |
| DK0911342T4 (da) * | 1997-04-15 | 2013-07-29 | Daiichi Sankyo Co Ltd | Nyt protein og fremgangsmåde til fremstilling deraf |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| BR9808545A (pt) * | 1997-04-16 | 2000-05-23 | Amgen Inc | ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento |
| PT2009025E (pt) | 1998-05-14 | 2011-09-19 | Immunex Corp | Método de inibição da actividade dos osteoclastos |
| US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| US8113839B2 (en) | 2000-07-21 | 2012-02-14 | Sony Corporation | Information processing apparatus, information processing method, information processing system, and storage medium |
| DE60129254T2 (de) | 2000-09-22 | 2008-03-13 | Immunex Corp., Thousand Oaks | Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b |
| ZA200305995B (en) | 2001-01-05 | 2004-08-04 | Pfizer | Antibodies to insulin-like growth factor I receptor. |
| PH12012502439A1 (en) * | 2001-06-26 | 2013-06-17 | Amgen Inc | Antibodies to opgl |
| JP4761710B2 (ja) | 2002-04-05 | 2011-08-31 | アムジェン インコーポレイテッド | 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体 |
| WO2004024752A1 (ja) | 2002-09-11 | 2004-03-25 | Chugai Seiyaku Kabushiki Kaisha | タンパク質精製方法 |
| ES2338105T3 (es) * | 2003-05-14 | 2010-05-04 | Kenta Biotech Ag | Anticuerpo monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 06 pseudomonas aeruginosa. |
| US7288253B2 (en) | 2003-08-08 | 2007-10-30 | Amgen Fremont, Inc. | Antibodies directed to parathyroid hormone (PTH) and uses thereof |
| US7318925B2 (en) * | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
| ME01198B (me) * | 2003-11-05 | 2013-03-20 | Ares Trading Sa | Prečišćavanje il-18 vezujućeg proteina |
| TWI359026B (en) * | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
| US7709611B2 (en) | 2004-08-04 | 2010-05-04 | Amgen Inc. | Antibodies to Dkk-1 |
| US20060115901A1 (en) * | 2004-10-22 | 2006-06-01 | Bahram Valamehr | Method and media for single cell serum-free culture of CHO cells |
| TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| CN101218247A (zh) | 2005-04-11 | 2008-07-09 | 米德列斯公司 | 利用hcic和离子交换层析的蛋白质纯化 |
| AU2015242973C1 (en) * | 2005-06-14 | 2018-07-05 | Amgen Inc. | Self-buffering protein formulations |
| EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | SELF-BUFFING PROTEIN FORMULATIONS |
| WO2007016562A2 (en) * | 2005-07-29 | 2007-02-08 | Amgen Inc. | Formulations that inhibit protein aggregation |
| PE20070684A1 (es) * | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| CA2822302A1 (en) † | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Methods of impairing osteoclast differentiation |
| WO2007125605A1 (ja) * | 2006-04-28 | 2007-11-08 | Kyoritsu Seiyaku Corporation | 動物由来蛋白なしで培養可能な猫の細胞、これを用いたウイルスの生産方法、及びワクチンの生産方法 |
| JP2010501623A (ja) | 2006-08-28 | 2010-01-21 | アレス トレーディング ソシエテ アノニム | Ｆｃ含有タンパク質の精製法 |
| WO2009131553A2 (en) * | 2006-12-29 | 2009-10-29 | Osteogenex Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| MX2009010179A (es) * | 2007-03-22 | 2010-03-15 | Imclone Llc | Formulaciones estables de anticuerpo. |
| EP2152747B1 (en) | 2007-05-24 | 2018-01-03 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| SI2188313T1 (en) | 2007-08-21 | 2018-04-30 | Amgen, Inc. | HUMAN C-FMS ANTIGEN TRANSFER PROTEIN |
| JP5963341B2 (ja) | 2007-09-14 | 2016-08-10 | アムジエン・インコーポレーテツド | 均質な抗体集団 |
| CA2701032C (en) | 2007-09-27 | 2021-01-26 | Amgen Inc. | Pharmaceutical formulations |
| RU2475499C2 (ru) | 2007-10-11 | 2013-02-20 | Дайити Санкио Компани, Лимитед | Антитело, направленное на белок siglec-15, связанный с остеокластами |
| EP3381445B1 (en) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| DK2250251T3 (en) | 2008-01-09 | 2018-01-22 | Sartorius Stedim Cellca Gmbh | Improved culture medium additive and method of using it |
| WO2009099641A2 (en) * | 2008-02-07 | 2009-08-13 | Amgen Inc. | Stabilized protein compositions |
| CL2009001735A1 (es) | 2008-08-19 | 2010-02-19 | Regeneron Pharma | Anticuerpo humano o fragmento de union a antigeno del mismo que une e inhibe actividad de ligando del activador del receptor de nf-kb (rankl); adn codificante; vector de expresion; metodo para producir dicho anticuerpo; composicion farmaceutica que lo comprende; uso para atenuar o inhibir enfermedad o condicion mediada por rankl |
| JP2012518400A (ja) | 2009-02-24 | 2012-08-16 | グラクソ グループ リミテッド | 多価および／または複数特異的ｒａｎｋｌ結合性構築物 |
| US20110305693A1 (en) * | 2009-02-24 | 2011-12-15 | Glaxo Group Limited | Anitigen-binding constructs |
| US20110305692A1 (en) | 2009-02-24 | 2011-12-15 | Glaxo Group Limited | Antigen-binding contructs |
| NZ605450A (en) | 2009-04-09 | 2014-07-25 | Daiichi Sankyo Co Ltd | Anti-siglec-15 antibody |
| EP2490957B1 (en) | 2009-10-23 | 2016-11-23 | Amgen, Inc | Vial adapter and system |
| ES2730828T3 (es) | 2010-02-01 | 2019-11-12 | Rebiotix Inc | Bacterioterapia para la colitis por Clostridium difficile |
| RS54291B2 (sr) | 2010-06-07 | 2023-12-29 | Amgen Inc | Uređaj za isporuku lekova |
| JP5699030B2 (ja) * | 2010-07-05 | 2015-04-08 | Ａｘｉｓ株式会社 | エタネルセプトを含む線維筋痛症の治療剤 |
| US9114131B2 (en) | 2010-10-05 | 2015-08-25 | Daiichi Sankyo Company, Limited | Antibody targeting osteoclast-related protein Siglec-15 |
| JP6159254B2 (ja) | 2010-10-06 | 2017-07-12 | フンダシオ インスティトゥト デ レセルカ ビオメディカ（イエレベ バルセロナ） | 乳がん転移の診断、予後診断、および処置のための方法 |
| US9480624B2 (en) | 2011-03-31 | 2016-11-01 | Amgen Inc. | Vial adapter and system |
| CA3021845C (en) | 2011-04-20 | 2022-03-29 | Amgen Inc. | Autoinjector apparatus |
| WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| EP2714736A1 (en) | 2011-05-27 | 2014-04-09 | Ablynx N.V. | Inhibition of bone resorption with rankl binding peptides |
| IL308846B2 (en) | 2011-10-14 | 2025-03-01 | Amgen Inc | Injector and assembly method |
| HK1198689A1 (en) | 2011-10-25 | 2015-05-29 | Prothena Biosciences Limited | Antibody formulations and methods |
| US9353153B2 (en) | 2012-02-09 | 2016-05-31 | Riken | Cyclic RNA and protein production method |
| RU2014143798A (ru) | 2012-03-30 | 2016-05-27 | Дайити Санкио Компани, Лимитед | Антитело к сиглек-15 с модифицированной cdr |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| US9150645B2 (en) * | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| US9695244B2 (en) * | 2012-06-01 | 2017-07-04 | Momenta Pharmaceuticals, Inc. | Methods related to denosumab |
| WO2013182912A2 (en) | 2012-06-06 | 2013-12-12 | Fundacio Privada Institut De Recerca Biomedica | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| CN104507969A (zh) | 2012-07-19 | 2015-04-08 | 阿莱斯亚生物疗法股份有限公司 | 抗siglec-15抗体 |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| EP2890782A1 (en) | 2012-09-02 | 2015-07-08 | AbbVie Inc. | Methods to control protein heterogeneity |
| SMT202000147T1 (it) | 2012-09-07 | 2020-05-08 | Coherus Biosciences Inc | Formulazioni acquose stabili di adalimumab |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| HK1213946A1 (zh) | 2012-10-12 | 2016-07-15 | Inbiomotion S.L. | 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法 |
| EP3081249B1 (en) | 2012-11-21 | 2020-12-30 | Amgen Inc. | Drug delivery device |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| DK2948553T3 (da) | 2013-01-25 | 2020-06-29 | Baylor College Medicine | Hjælper-afhængigt afgivelses- og ekspressionssystem til adenoviral genterapi |
| CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| EP2855533A4 (en) | 2013-03-15 | 2015-11-25 | Momenta Pharmaceuticals Inc | METHODS RELATING TO CTLA4-FC FUSION PROTEINS |
| TWI639449B (zh) | 2013-03-15 | 2018-11-01 | 美商安美基公司 | 用於注射器之匣盒 |
| US20160032399A1 (en) | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| TWI580451B (zh) | 2013-03-15 | 2017-05-01 | 安美基公司 | 用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法 |
| US20160032400A1 (en) | 2013-03-15 | 2016-02-04 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| TWI592183B (zh) | 2013-03-15 | 2017-07-21 | 安美基公司 | 本體輪廓可調適之自動注射器裝置 |
| KR102287687B1 (ko) | 2013-03-22 | 2021-08-06 | 암젠 인크 | 인젝터 및 조립 방법 |
| US10464996B2 (en) | 2013-05-13 | 2019-11-05 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| US9481901B2 (en) | 2013-05-30 | 2016-11-01 | Amgen Inc. | Methods for increasing mannose content of recombinant proteins |
| US9511099B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| US9694039B2 (en) | 2013-06-05 | 2017-07-04 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| US9511100B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| US9782445B2 (en) | 2013-06-05 | 2017-10-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| HUE040211T2 (hu) | 2013-06-05 | 2019-02-28 | Rebiotix Inc | Mikrobióta-helyreállítási terápia (MRT), készítmények és elõállítási eljárások |
| US10383901B2 (en) | 2013-06-05 | 2019-08-20 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| WO2015018421A1 (en) | 2013-08-07 | 2015-02-12 | Rigshospitalet Copenhagen University Hospital | Antibodies, compounds and derivatives thereof for use in the treatment of male infertility |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| US20160207988A1 (en) * | 2013-09-24 | 2016-07-21 | The Board Of Regents Of The University Of Texas System | A novel hormone that promotes bone resorption and uses thereof |
| WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| KR20160061424A (ko) | 2013-10-09 | 2016-05-31 | 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) | 유방암으로부터 기원하는 골의 전이성 암의 예후 및 치료 방법 |
| US20160257754A1 (en) | 2013-10-16 | 2016-09-08 | Momenta Pharmaceuticals Inc. | Sialylated glycoproteins |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| EP3789064B1 (en) | 2013-10-24 | 2024-11-27 | Amgen Inc. | Injector and method of assembly |
| US10758683B2 (en) | 2013-10-24 | 2020-09-01 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
| RU2656153C1 (ru) * | 2013-12-20 | 2018-05-31 | Девелопмент Сентер Фор Байотекнолоджи | Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии |
| CN103965357B (zh) * | 2013-12-31 | 2016-08-17 | 嘉和生物药业有限公司 | 一种抗人rankl抗体 |
| US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
| HRP20200711T1 (hr) | 2014-03-10 | 2020-07-24 | Richter Gedeon Nyrt. | Pročišćavanje imunoglobulina korištenjem koraka prethodnog čišćenja |
| HRP20251500T1 (hr) | 2014-03-28 | 2026-01-02 | Duke University | Liječenje raka dojke pozitivnog na receptor estrogena uporabom selektivnih modulatora receptora estrogena |
| CA2945026C (en) | 2014-05-07 | 2023-10-10 | Amgen Inc. | Autoinjector with shock reducing elements |
| EP4362039A3 (en) | 2014-06-03 | 2024-08-07 | Amgen Inc. | Controllable drug delivery system and method of use |
| HUE042277T2 (hu) * | 2014-06-04 | 2019-06-28 | Amgen Inc | Eljárások fehérjék begyûjtésére emlõssejttenyészetekbõl |
| MX2021014323A (es) | 2014-10-14 | 2023-02-02 | Amgen Inc | Dispositivo de inyección de fármaco con indicadores visuales y audibles. |
| US10793642B2 (en) | 2014-12-11 | 2020-10-06 | Inbiomotion S.L. | Binding members for human c-MAF |
| ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
| ES2898469T3 (es) | 2014-12-19 | 2022-03-07 | Amgen Inc | Dispositivo de administración de medicamentos con sensor de proximidad |
| CA2976935C (en) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
| US10111928B1 (en) * | 2015-02-25 | 2018-10-30 | Saint Louis University | Pulsed introduction of low-dose RANKL as a therapy for osteogenesis imperfecta |
| US10328123B2 (en) | 2015-02-25 | 2019-06-25 | Saint Louis University | Pulsed introduction of low-dose RANKL as a therapy for atherosclerosis |
| US10745461B2 (en) | 2015-02-25 | 2020-08-18 | Saint Louis University | Pulsed introduction of low-dose RANKL as a therapy for diet-induced atherosclerosis |
| EP3981450A1 (en) | 2015-02-27 | 2022-04-13 | Amgen, Inc | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
| SG10202104177VA (en) | 2015-04-29 | 2021-05-28 | Radius Pharmaceuticals Inc | Methods of treating cancer |
| US10905726B2 (en) | 2015-06-09 | 2021-02-02 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
| US10799539B2 (en) | 2015-06-09 | 2020-10-13 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
| ES2889902T3 (es) | 2015-06-09 | 2022-01-14 | Rebiotix Inc | Métodos de fabricación de composiciones para terapia de restauración de la microbiota (TRM) |
| US10828340B2 (en) | 2015-06-09 | 2020-11-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
| HU231463B1 (hu) | 2015-08-04 | 2024-01-28 | Richter Gedeon Nyrt. | Módszer rekombináns proteinek galaktóz tartalmának növelésére |
| ES2964640T3 (es) | 2015-08-13 | 2024-04-08 | Amgen Inc | Filtración en profundidad cargada de proteínas de unión al antígeno |
| WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| ES2755717T3 (es) | 2015-12-09 | 2020-04-23 | Amgen Inc | Autoinyector con tapa de señalización |
| US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
| TWI742054B (zh) | 2016-03-08 | 2021-10-11 | 美商健生生物科技公司 | Ｇｉｔｒ抗體，方法及用途 |
| EP4035711B1 (en) | 2016-03-15 | 2025-06-04 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
| WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
| US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
| US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
| ES2959783T3 (es) | 2016-05-13 | 2024-02-28 | Amgen Inc | Conjunto de cubierta protectora de vial |
| WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
| KR102571924B1 (ko) | 2016-05-25 | 2023-08-28 | 인바이오모션 에스.엘. | c-MAF 상태에 기초한 유방암의 치료 |
| EP3465124A1 (en) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
| US11285266B2 (en) | 2016-07-01 | 2022-03-29 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
| IL264161B2 (en) | 2016-07-14 | 2025-06-01 | Scholar Rock Inc | Tgfb antibodies, methods, and uses |
| US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
| SG11201903521XA (en) | 2016-10-21 | 2019-05-30 | Amgen Inc | Pharmaceutical formulations and methods of making the same |
| EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| AU2018205285C9 (en) | 2017-01-05 | 2024-05-23 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD1901-2HCl |
| US20190358411A1 (en) | 2017-01-17 | 2019-11-28 | Amgen Inc. | Injection devices and related methods of use and assembly |
| CA3052204A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
| JP7064501B2 (ja) | 2017-02-17 | 2022-05-10 | アムジエン・インコーポレーテツド | 無菌流体流路を備える薬物送達デバイスおよび関連する組立方法 |
| CA3050927A1 (en) | 2017-03-06 | 2018-09-13 | Brian Stonecipher | Drug delivery device with activation prevention feature |
| IL268478B2 (en) | 2017-03-07 | 2023-10-01 | Amgen Inc | Inserting a needle using super pressure |
| CA3052310A1 (en) | 2017-03-09 | 2018-09-13 | Amgen Inc. | Insertion mechanism for drug delivery device |
| HUE063805T2 (hu) | 2017-03-28 | 2024-01-28 | Amgen Inc | Dugattyúrúd és fecskendõ összeállító rendszer és eljárás |
| JOP20190255A1 (ar) | 2017-04-28 | 2019-10-27 | Amgen Inc | صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| AU2018280054B2 (en) | 2017-06-08 | 2023-07-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
| MX2019014615A (es) | 2017-06-08 | 2020-02-07 | Amgen Inc | Dispositivo de administracion de farmacos accionado por par de torsion. |
| EP3641857A1 (en) | 2017-06-22 | 2020-04-29 | Amgen Inc. | Device activation impact/shock reduction |
| AU2018290302B2 (en) | 2017-06-23 | 2024-02-29 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
| ES2972207T3 (es) | 2017-07-14 | 2024-06-11 | Amgen Inc | Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble |
| JP7649105B2 (ja) | 2017-07-21 | 2025-03-19 | アムジエン・インコーポレーテツド | 薬物容器のためのガス透過性シーリング部材及び組立方法 |
| MA49676A (fr) | 2017-07-25 | 2020-06-03 | Amgen Inc | Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé |
| US11617837B2 (en) | 2017-07-25 | 2023-04-04 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
| MA49838A (fr) | 2017-08-09 | 2020-06-17 | Amgen Inc | Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre |
| WO2019036181A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | BODY INJECTOR WITH STERILE ADHESIVE PATCH |
| US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
| US11759565B2 (en) | 2017-10-04 | 2023-09-19 | Amgen Inc. | Flow adapter for drug delivery device |
| EP3691716B1 (en) | 2017-10-06 | 2023-11-29 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
| EP3694578B1 (en) | 2017-10-09 | 2025-09-24 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
| MA50528A (fr) | 2017-11-03 | 2020-09-09 | Amgen Inc | Systèmes et approches pour stériliser un dispositif d'administration de médicament |
| EP3707075A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Fill-finish assemblies and related methods |
| MA50553A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Dispositif d'administration de médicament avec détection de positionnement et de débit |
| MX2020004736A (es) | 2017-11-10 | 2020-08-13 | Amgen Inc | Embolos para dispositivos de administracion de farmacos. |
| SG11202002772VA (en) | 2017-11-16 | 2020-04-29 | Amgen Inc | Autoinjector with stall and end point detection |
| WO2019099324A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
| US11654153B2 (en) | 2017-11-22 | 2023-05-23 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-MAF status |
| US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
| US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
| WO2020010216A1 (en) | 2018-07-04 | 2020-01-09 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad 1901-2hcl |
| MA53375A (fr) | 2018-07-24 | 2021-06-02 | Amgen Inc | Dispositifs d'administration pour l'administration de médicaments |
| CN112469454B (zh) | 2018-07-24 | 2024-01-26 | 安进公司 | 用于施用药物的输送装置 |
| WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
| WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
| US12109389B2 (en) | 2018-07-31 | 2024-10-08 | Amgen Inc. | Fluid path assembly for a drug delivery device |
| CA3106452A1 (en) | 2018-09-24 | 2020-04-02 | Amgen Inc. | Interventional dosing systems and methods |
| EP3856283A1 (en) | 2018-09-28 | 2021-08-04 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
| WO2020072577A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
| EP3860686A1 (en) | 2018-10-05 | 2021-08-11 | Amgen Inc. | Drug delivery device having dose indicator |
| EA202191037A1 (ru) | 2018-10-15 | 2021-08-05 | Эмджен Инк. | Устройство доставки лекарственного средства, имеющее демпферный механизм |
| AR116703A1 (es) | 2018-10-15 | 2021-06-02 | Amgen Inc | Proceso de ensamblaje de plataforma para un dispositivo de administración de fármacos |
| MA54048A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
| IL281908B2 (en) | 2018-11-01 | 2025-06-01 | Amgen Inc | Drug delivery devices with partial drug delivery member retraction |
| TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| HU231514B1 (hu) | 2018-11-07 | 2024-07-28 | Richter Gedeon Nyrt. | Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer |
| MA54946A (fr) | 2019-02-12 | 2021-12-22 | Radius Pharmaceuticals Inc | Procédés et composés |
| HU231498B1 (hu) | 2019-04-04 | 2024-05-28 | Richter Gedeon Nyrt | Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával |
| MX2021012557A (es) | 2019-04-24 | 2021-11-12 | Amgen Inc | Conjuntos y metodos de verificacion de esterilizacion de jeringuillas. |
| AU2020266083A1 (en) | 2019-04-30 | 2021-09-23 | Instituto de Medicina Molecular João Lobo Antunes | Rank pathway inhibitors in combination with CDK inhibitors |
| CA3148261A1 (en) | 2019-08-23 | 2021-03-04 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
| EP4110371A1 (en) | 2020-01-24 | 2023-01-04 | Radius Health, Inc. | Methods of stimulating bone growth with abalopartide and denosumab |
| CN113621060B (zh) * | 2020-05-07 | 2023-07-04 | 浙江瑞硕生物技术有限公司 | 一种opg抗体对及其应用 |
| EP4341161A1 (en) | 2021-05-21 | 2024-03-27 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
| WO2024064878A1 (en) | 2022-09-23 | 2024-03-28 | The University Of North Carolina At Chapel Hill | Methods and compositions for the treatment of melanoma |
| WO2024104409A1 (zh) * | 2022-11-16 | 2024-05-23 | 苏州盛迪亚生物医药有限公司 | 一种含抗rankl-ngf双特异性抗体的药物组合物 |
Family Cites Families (318)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4338397A (en) * | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4755465A (en) * | 1983-04-25 | 1988-07-05 | Genentech, Inc. | Secretion of correctly processed human growth hormone in E. coli and Pseudomonas |
| US4710457A (en) | 1983-06-29 | 1987-12-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibody for human hematopoietic glycoproteins and method |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| EP0192658A4 (en) | 1984-07-30 | 1987-07-13 | Salk Inst For Biological Studi | RETROVIRAL GENE TRANSFER VECTORS. |
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US4760130A (en) | 1984-12-06 | 1988-07-26 | Synergen Biologicals, Inc. | Serine protease inhibitors and methods for isolation of same |
| US5900400A (en) | 1984-12-06 | 1999-05-04 | Amgen Inc. | Serine protease inhibitor analogs |
| JPS6291197A (ja) | 1985-10-17 | 1987-04-25 | Dainippon Pharmaceut Co Ltd | 抗ヒトインタ−ロイキン１抗体，その製法及びその使用法 |
| US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| DK590387A (da) | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US5359032A (en) | 1987-08-26 | 1994-10-25 | Biogen Inc. | Interkeukin-1 inhibitor |
| US5512544A (en) | 1987-09-13 | 1996-04-30 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising an anticytokine |
| IL98078A0 (en) | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
| IL83878A (en) | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
| US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US5319071A (en) | 1987-11-25 | 1994-06-07 | Immunex Corporation | Soluble interleukin-1 receptors |
| US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
| US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
| GB8807803D0 (en) | 1988-03-31 | 1988-05-05 | Glaxo Group Ltd | Biochemical product |
| WO1989011540A1 (en) | 1988-05-27 | 1989-11-30 | Synergen, Inc. | Interleukin-1 inhibitors |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5359037A (en) | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
| US5811261A (en) | 1988-09-12 | 1998-09-22 | Yeda Research And Development Co. Ltd. | Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) |
| IL94039A (en) | 1989-08-06 | 2006-09-05 | Yeda Res & Dev | Antibodies to tbp - 1 and their use |
| DE68925935T2 (de) | 1988-10-01 | 1996-08-14 | Otsuka Pharma Co Ltd | Antikörper gegen Interleukin-1-beta |
| FR2640146B1 (fr) | 1988-12-08 | 1993-12-24 | Commissariat A Energie Atomique | Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE289350T1 (de) | 1989-04-21 | 2005-03-15 | Amgen Inc | Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas |
| DE3922089A1 (de) | 1989-05-09 | 1990-12-13 | Basf Ag | Neue proteine und ihre herstellung |
| CA2458875A1 (en) | 1989-05-18 | 1990-11-18 | Yeda Research And Development Company Limited | Tumor necrosis factor (tnf) binding protein ii, its purification and antibodies thereto |
| IL107267A (en) | 1993-10-12 | 2009-07-20 | Yeda Res & Dev | Ligand to a member of the tnf/ngf receptor family |
| AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
| US5627262A (en) | 1989-07-05 | 1997-05-06 | The Board Of Regents Of The University Of Oklahoma | Method and composition for the treatment of septic shock |
| IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
| CA2065346C (en) | 1989-09-05 | 2005-03-29 | Craig A. Smith | Tumor necrosis factor-.alpha. and-.beta. receptors |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| ATE236249T1 (de) | 1989-09-12 | 2003-04-15 | Hoffmann La Roche | Tfn-bindende proteine |
| JPH03127800A (ja) | 1989-10-13 | 1991-05-30 | Teijin Ltd | 腫瘍壊死因子活性抑制物質 |
| BR9007883A (pt) | 1989-11-29 | 1992-09-29 | Synergen Inc | Producao de inibidor de interleucina-1 humana recombinante |
| JPH0578396A (ja) | 1989-12-13 | 1993-03-30 | Yeda Res & Dev Co Ltd | ヒト腫瘍壊死因子結合蛋白 |
| US5136021A (en) | 1990-02-27 | 1992-08-04 | Health Research, Inc. | TNF-inhibitory protein and a method of production |
| AU649245B2 (en) | 1990-04-02 | 1994-05-19 | Amgen, Inc. | Methods for treating interleukin-1 mediated diseases |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| AU7683391A (en) | 1990-04-27 | 1991-11-27 | Upjohn Company, The | Modified interleukin-1 inhibitors |
| US5872095A (en) | 1990-05-01 | 1999-02-16 | Chiron Corporation | IL-1 receptor antagonists medicaments |
| ATE178094T1 (de) | 1990-05-01 | 1999-04-15 | Chiron Corp | Interleukin-i antagonist und seine verwendung |
| US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
| GB2246569A (en) | 1990-06-15 | 1992-02-05 | Charing Cross Sunley Research | Tumour necrosis factor - alpha binding protein |
| US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| EP1586635A1 (de) | 1990-06-28 | 2005-10-19 | Hoechst Aktiengesellschaft | Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung |
| WO1992001002A1 (en) | 1990-07-11 | 1992-01-23 | Teijin Limited | Tumor necrosis factor activity inhibitor and production thereof |
| WO1992002220A1 (en) | 1990-08-03 | 1992-02-20 | Smithkline Beecham Corporation | Tnf inhibitors |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5747444A (en) | 1990-10-09 | 1998-05-05 | Chiron Corporation | Method of treating graft-versus-host disease |
| GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
| US5858355A (en) | 1990-12-20 | 1999-01-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | IRAP gene as treatment for arthritis |
| NZ241311A (en) | 1991-01-17 | 1995-03-28 | Gen Hospital Corp | Rna sequence having trans-splicing activity, plant strains |
| GEP20002142B (en) | 1991-01-18 | 2000-06-25 | Amgen Inc | Method for Treatment and Prevention of TNF Mediated Diseases |
| DE69233069T2 (de) | 1991-03-15 | 2003-11-27 | Amgen Inc., Thousand Oaks | Pegylation von polypeptiden |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| US5770401A (en) | 1991-10-15 | 1998-06-23 | Mullarkey; Michael F. | Methods and compositions for treating allergic reactions |
| JP3308534B2 (ja) | 1991-10-25 | 2002-07-29 | イミュネックス・コーポレーション | 新規なサイトカイン |
| US5961974A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
| ES2038546B1 (es) | 1991-11-08 | 1994-02-16 | Andromaco Lab | Procedimiento de obtencion de un producto de naturaleza polipeptidica con actividad inhibidora de la hiperproduccion del factor de necrosis tumoral. |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| MX9300141A (es) | 1992-01-13 | 1994-07-29 | Smithkline Beecham Corp | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| KR950700066A (ko) | 1992-03-04 | 1995-01-16 | 제프리 비. 오스터 | 거울상이성체성 하이드록시화 크산틴 화합물(Enantiomeric hydroxylated xanthine compounds) |
| NZ251820A (en) | 1992-03-30 | 1996-07-26 | Immunex Corp | Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide |
| WO1993021946A1 (en) | 1992-04-30 | 1993-11-11 | Synergen, Inc. | Methods for treating interleukin-1 and tumor necrosis factor mediated diseases |
| JPH05312248A (ja) | 1992-05-08 | 1993-11-22 | Nissan Motor Co Ltd | シフトレバー装置 |
| DE4219626A1 (de) | 1992-06-16 | 1993-12-23 | Wehling Peter Priv Doz Dr Med | Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen |
| JPH0630788A (ja) | 1992-07-16 | 1994-02-08 | Otsuka Pharmaceut Co Ltd | ヒトインターロイキン−１に対する組換え抗体 |
| US5545716A (en) | 1992-09-08 | 1996-08-13 | University Of Florida | Superantigen agonist and antagonist peptides |
| PT661992E (pt) | 1992-09-17 | 2004-05-31 | Amgen Inc | Formulacoes farmaceuticas de inibidores de interleucina-1 |
| JPH06111399A (ja) | 1992-09-30 | 1994-04-22 | Sony Corp | 光磁気記録媒体及びその製造方法 |
| US5646154A (en) | 1992-10-07 | 1997-07-08 | Sumitomo Pharmaceuticals Co., Ltd. | Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor |
| DE69332981T2 (de) | 1992-10-23 | 2004-05-19 | Immunex Corp., Seattle | Methoden zur herstellung löslicher, oligomerer proteine |
| US5891438A (en) * | 1992-10-30 | 1999-04-06 | The Regents Of The University Of California | Method for stimulating production of variable region gene family restricted antibodies through B-cell superantigen vaccination |
| US5866576A (en) | 1992-12-16 | 1999-02-02 | Cell Therapeutics, Inc. | Epoxide-containing compounds |
| EP0607776B1 (de) | 1993-01-08 | 1998-12-09 | Hoechst Aktiengesellschaft | Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha |
| PT614984E (pt) | 1993-03-05 | 2001-12-28 | Bayer Ag | Anticorpos humanos anti-tnf |
| EP0701563A4 (en) | 1993-03-08 | 1997-07-02 | Univ Pittsburgh | GEN TRANSFER FOR TREATING CONSTRUCTIVE TISSUE OF A MAMMAL HOST |
| DE69431620T2 (de) | 1993-03-19 | 2003-07-03 | Vacsyn S.A., Paris | Zusammensetzungen für die anwendung in menschlicher therapie, charakterisiert durch die assoziation eines muramylpeptids mit einem cytokin |
| US6326353B1 (en) | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
| US5843905A (en) | 1993-06-04 | 1998-12-01 | Vertex Pharmaceuticals, Incorporated | Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors |
| FR2706772A1 (en) | 1993-06-22 | 1994-12-30 | Vacsyn Sa | Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| ES2176251T3 (es) | 1993-07-28 | 2002-12-01 | Aventis Pharma Ltd | Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf). |
| ATE177083T1 (de) | 1993-11-29 | 1999-03-15 | Merrell Pharma Inc | Benzolsulfonyliminderivate als inhibitoren der il-1 wirkung |
| CA2138305A1 (en) | 1993-12-28 | 1995-06-29 | Naohito Ohashi | Tumor necrosis factor production inhibitors |
| GB9401460D0 (en) | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
| US5608035A (en) | 1994-02-02 | 1997-03-04 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
| WO1995022546A1 (en) | 1994-02-18 | 1995-08-24 | Cell Therapeutics, Inc. | Intracellular signalling mediators |
| CA2185019C (en) | 1994-03-09 | 2000-08-08 | Pfizer Limited | Isoxazoline compounds as inhibitors of tnf release |
| US5708142A (en) | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
| US5741667A (en) | 1994-05-27 | 1998-04-21 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
| US5817822A (en) | 1994-06-24 | 1998-10-06 | Novartis Corporation | Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids |
| IL114417A0 (en) | 1994-07-07 | 1995-10-31 | Res Dev Foundation | Tumor necrosis factor receptor-I associated proteins and protein kinase and methods for their use |
| US5877180A (en) | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
| DE69519454T2 (de) | 1994-07-14 | 2001-05-03 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama | Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen |
| US5641747A (en) | 1994-07-25 | 1997-06-24 | Temple University-Of The Commonwealth System Of Higher Education | Treatment of osteopetrotic diseases |
| US5633227A (en) | 1994-09-12 | 1997-05-27 | Miles, Inc. | Secretory leukocyte protease inhibitor as an inhibitor of tryptase |
| IT1269989B (it) | 1994-09-21 | 1997-04-16 | Dompe Spa | Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria |
| FI971412A0 (fi) | 1994-10-05 | 1997-04-04 | Chiroscience Ltd | Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä |
| US5852173A (en) | 1994-10-19 | 1998-12-22 | Genetics Institute, Inc. | TNF receptor death ligand proteins and inhibitors of ligand binding |
| TW464656B (en) | 1994-11-15 | 2001-11-21 | Hayashibara Biochem Lab | Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease |
| WO1996019990A1 (en) | 1994-12-23 | 1996-07-04 | Smithkline Beecham Corporation | 4,4-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds |
| ZA9510826B (en) | 1994-12-23 | 1996-06-20 | Smithkline Beecham Corp | 3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds |
| US6323201B1 (en) | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
| US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| CA2209555A1 (en) | 1995-01-09 | 1996-07-18 | Otsuka Pharmaceutical Co., Ltd. | Tnf-.alpha. inhibitor |
| PE64396A1 (es) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| US6001349A (en) | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
| BR9607336A (pt) | 1995-02-23 | 1997-11-25 | Novartis Nutrition Ag | Composições de aminoácidos e utilidades das mesmas em nutrição clinica |
| WO1996028546A1 (en) | 1995-03-15 | 1996-09-19 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
| EP0737471A3 (fr) | 1995-04-10 | 2000-12-06 | L'oreal | Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue |
| US5861510A (en) | 1995-04-20 | 1999-01-19 | Pfizer Inc | Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors |
| EP0822984A4 (en) | 1995-04-27 | 2000-05-03 | Human Genome Sciences Inc | TUMOR NECROSIS FACTOR RECEPTORS IN MEN |
| JPH11505532A (ja) | 1995-05-10 | 1999-05-21 | カイロサイエンス・リミテッド | 金属プロテアーゼとｔｎｆの放出を抑制するペプチド化合物およびその治療的使用 |
| AR004471A1 (es) | 1995-05-31 | 1998-12-16 | Smithkline Beecham Corp | Compuestos de ciclohexan-1-ol-4,4-disustituidos, utiles en el tratamiento de enfermedades alergicas e inflamatorias y composiciones farmaceuticas que lascontienen |
| US5817476A (en) | 1995-06-07 | 1998-10-06 | Genetics Institute, Inc. | Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins |
| US5739143A (en) | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| JP3279573B2 (ja) | 1995-06-07 | 2002-04-30 | イミュネックス・コーポレーション | 新規の変異型ｃｄ４０ｌ |
| US5830742A (en) | 1995-06-08 | 1998-11-03 | Immunex Corporation | TNF-α converting enzyme |
| JP4435304B2 (ja) | 1995-06-29 | 2010-03-17 | イミュネックス・コーポレーション | アポトーシスを誘導するサイトカイン |
| US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
| ZA966663B (en) | 1995-08-17 | 1998-02-06 | Genentech Inc | Traf Inhibitors. |
| US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
| JPH11511463A (ja) | 1995-08-31 | 1999-10-05 | スミスクライン・ビーチャム・コーポレイション | インターロイキン変換酵素およびアポプトーシス |
| IL115245A (en) | 1995-09-11 | 2002-12-01 | Yissum Res Dev Co | Tumor necrosis factor inhibiting pharmaceuticals |
| WO1997012244A1 (en) | 1995-09-27 | 1997-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining t-cell profiles of immunocompromised subjects |
| CN1145637C (zh) | 1995-10-05 | 2004-04-14 | 达尔文发现有限公司 | 作为金属蛋白酶和tnf释放抑制剂的硫取代的肽 |
| DE19540475A1 (de) | 1995-10-20 | 1997-04-24 | Schering Ag | Chirale Methylphenyloxazolidinone |
| US6281352B1 (en) | 1995-11-14 | 2001-08-28 | Dupont Pharmaceuticals Company | Macrocyclic compounds as metalloprotease inhibitors |
| EE9800115A (et) | 1995-11-14 | 1998-10-15 | The Du Pont Merck Pharmaceutical Company | Uudsed makrotsüklilised ühendid kui metalloproteaasi inhibiitorid |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| CO4750805A1 (es) * | 1995-12-13 | 1999-03-31 | Sumitomo Chemical Co | Compuesto para champu |
| US5869315A (en) | 1995-12-18 | 1999-02-09 | Basf Aktiengesellschaft | Modified interleukin-1β converting enzyme with increased stability |
| US5891883A (en) | 1995-12-21 | 1999-04-06 | Smithkline Beecham Corporation | 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds |
| US5869677A (en) | 1995-12-21 | 1999-02-09 | Smithkline Beecham Corporation | 3,3-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds |
| US5990119A (en) | 1995-12-21 | 1999-11-23 | Smithkline Beecham Corporation | 1,4,4-(trisubstituted)cyclohexane monomers and related compounds |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| US6613544B1 (en) * | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| AU1341797A (en) | 1995-12-29 | 1997-07-28 | Incyte Pharmaceuticals, Inc. | Nucleic acids encoding interferon gamma inducing factor-2 |
| US6046048A (en) | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
| CN1300173C (zh) | 1996-02-09 | 2007-02-14 | 艾博特生物技术有限公司 | 结合人TNFα的人抗体 |
| CA2539273C (en) | 1996-02-09 | 2014-02-04 | Amgen Inc. | A fusion protein comprising an interleukin-1 receptor antagonist and uses thereof |
| US5994351A (en) | 1998-07-27 | 1999-11-30 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| US5981220A (en) | 1996-03-27 | 1999-11-09 | Human Genome Sciences, Inc. | Epidermal differentiation factor |
| GB9607249D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
| GB9607119D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
| GB9607120D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
| US5710013A (en) | 1996-04-19 | 1998-01-20 | Tularik Inc. | Tumor necrosis factor receptor associated factor 6 (TRAF6) |
| GB9609795D0 (en) | 1996-05-10 | 1996-07-17 | Smithkline Beecham Plc | Novel compounds |
| AUPO048296A0 (en) | 1996-06-14 | 1996-07-11 | Fujisawa Pharmaceutical Co., Ltd. | New compound and its preparation |
| US6060283A (en) | 1996-06-27 | 2000-05-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding human interleukin-18 (IL-18, interferon-γ inducing factor) |
| EP0818439B1 (en) | 1996-07-02 | 1999-10-13 | Nisshin Flour Milling Co., Ltd. | Imide derivatives |
| TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
| JPH10130149A (ja) | 1996-07-12 | 1998-05-19 | Sankyo Co Ltd | Ｔｎｆ産生抑制剤 |
| US5853977A (en) | 1996-07-12 | 1998-12-29 | Schering Corporation | Mammalian TNF-α convertases |
| US5877222A (en) | 1996-07-19 | 1999-03-02 | The Regents Of The University Of California | Method for treating aids-associated dementia |
| GB9616643D0 (en) | 1996-08-08 | 1996-09-25 | Chiroscience Ltd | Compounds |
| KR100539031B1 (ko) | 1996-08-12 | 2005-12-27 | 셀진 코포레이션 | 면역치료제 및 이를 이용하여 사이토카인 농도를감소시키는 방법 |
| US6069132A (en) | 1996-08-14 | 2000-05-30 | Revanker; Ganapathi R. | Phosphazole compounds |
| WO1998013348A1 (en) | 1996-09-25 | 1998-04-02 | Ss Pharmaceutical Co., Ltd. | Substituted vinylpyridine derivatives and drugs containing the same |
| US5962481A (en) | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| GB9621859D0 (en) | 1996-10-21 | 1996-12-11 | Xenova Ltd | Cytokine production inhibitors |
| GB9712761D0 (en) | 1997-06-17 | 1997-08-20 | Chiroscience Ltd | Quinolines and their therapeutic use |
| JPH10147531A (ja) | 1996-11-19 | 1998-06-02 | Otsuka Pharmaceut Co Ltd | ＴＮＦ−α産生抑制剤 |
| WO1998021957A1 (en) | 1996-11-20 | 1998-05-28 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
| US5955480A (en) | 1996-11-20 | 1999-09-21 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
| US5834435A (en) | 1996-11-27 | 1998-11-10 | Slesarev; Vladimir I. | Inhibition of TNF-α pleiotropic and cytotoxic effects |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| PT942740E (pt) | 1996-12-06 | 2004-01-30 | Amgen Inc | Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf |
| PT1114864E (pt) | 1996-12-13 | 2008-10-08 | Schering Corp | Antigénios de superfície de células de mamífero, reagentes relacionados |
| DE19652227A1 (de) | 1996-12-16 | 1998-06-18 | Bosch Gmbh Robert | Verfahren und Vorrichtung zum Zuordnen einer Fernbedienung zu einer Basisstation |
| JPH10231285A (ja) | 1996-12-17 | 1998-09-02 | Ishihara Sangyo Kaisha Ltd | フタルイミド誘導体又はその塩、それらの製造方法及びそれらを含有する医薬組成物 |
| WO1998028423A2 (en) | 1996-12-20 | 1998-07-02 | Board Of Regents, The University Of Texas System | Compositions and methods of use for osteoclast inhibitory factors |
| US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| EP2003203A1 (en) | 1996-12-23 | 2008-12-17 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily |
| US7141393B2 (en) | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
| PT853083E (pt) | 1997-01-06 | 2001-12-28 | Pfizer | Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica |
| US5952320A (en) | 1997-01-07 | 1999-09-14 | Abbott Laboratories | Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion |
| ZA9818B (en) | 1997-01-07 | 1998-07-02 | Abbott Lab | C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion |
| US6054559A (en) | 1997-01-28 | 2000-04-25 | Smithkline Beecham Corporation | Interleukin-1 receptor antagonist beta (IL-1raβ) |
| PL335052A1 (en) | 1997-01-29 | 2000-03-27 | Pfizer | Derivatives of sulphonylurea and their application in regulating activity of interleukin-1 |
| JP3955352B2 (ja) | 1997-02-25 | 2007-08-08 | 株式会社林原生物化学研究所 | 破骨細胞形成阻害剤 |
| US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
| US6476027B1 (en) | 1997-03-04 | 2002-11-05 | Monsanto Company | N-hydroxy 4-sulfonyl butanamide compounds |
| WO1998039326A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
| ES2234103T3 (es) | 1997-03-04 | 2005-06-16 | Pharmacia Corporation | Compuestos de acido tioarilsulfonamidohidroxamico. |
| US6380258B2 (en) | 1997-03-04 | 2002-04-30 | G. D. Searle, L.L.C. | Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| US6638952B1 (en) | 1997-03-04 | 2003-10-28 | Pharmacia Corporation | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
| US6087116A (en) | 1997-03-12 | 2000-07-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18 (IL-18) receptor polypeptides and their uses |
| HUP0104439A3 (en) | 1997-03-18 | 2002-08-28 | Basf Ag | Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof |
| JPH10259140A (ja) | 1997-03-18 | 1998-09-29 | Sumitomo Pharmaceut Co Ltd | 腫瘍壊死因子産生抑制剤 |
| US6054487A (en) | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
| AU6769298A (en) | 1997-03-21 | 1998-10-20 | Cistron Biotechnology, Inc. | Method for inhibiting cleavage of precursor il-1beta |
| GB9706255D0 (en) | 1997-03-26 | 1997-05-14 | Smithkline Beecham Plc | Novel compounds |
| EP0971881A1 (en) | 1997-03-28 | 2000-01-19 | AstraZeneca AB | Process for the preparation of n-(3-hydroxy-succinyl)-amino acid derivatives |
| EP0971895A1 (en) | 1997-03-28 | 2000-01-19 | AstraZeneca AB | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor |
| EA003528B1 (ru) | 1997-04-04 | 2003-06-26 | Пфайзер Продактс Инк. | Производные никотинамида, их применение, фармацевтическая композиция, способ лечения и способ ингибирования изоферментов фдэ4 d |
| ATE297755T1 (de) | 1997-04-10 | 2005-07-15 | Agennix Inc | Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind |
| DK0911342T4 (da) | 1997-04-15 | 2013-07-29 | Daiichi Sankyo Co Ltd | Nyt protein og fremgangsmåde til fremstilling deraf |
| EP0977851A2 (en) | 1997-04-15 | 2000-02-09 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| BR9808545A (pt) | 1997-04-16 | 2000-05-23 | Amgen Inc | ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento |
| US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| FR2762315B1 (fr) | 1997-04-22 | 1999-05-28 | Logeais Labor Jacques | Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha |
| IL132318A0 (en) | 1997-04-24 | 2001-03-19 | Ortho Mcneil Pharm Inc | Substituted imidazoles useful in the treatment of inflammatory diseases |
| CA2229449A1 (en) | 1997-04-25 | 1998-10-25 | Takeda Chemical Industries, Ltd. | Novel receptor protein and its use |
| FR2762514B1 (fr) | 1997-04-29 | 1999-10-22 | Sanofi Sa | Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation |
| JP3776203B2 (ja) | 1997-05-13 | 2006-05-17 | 第一製薬株式会社 | Ｉｃａｍ−１産生阻害剤 |
| PL336990A1 (en) | 1997-05-22 | 2000-07-31 | Searle & Co | 3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38 |
| WO1998054201A1 (en) | 1997-05-29 | 1998-12-03 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
| US6265535B1 (en) | 1997-05-30 | 2001-07-24 | The Trustees Of The University Of Pennsylvania | Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses |
| JPH111481A (ja) | 1997-06-10 | 1999-01-06 | Sumitomo Pharmaceut Co Ltd | ピペリジニルフタラジン誘導体 |
| SK286940B6 (sk) | 1997-06-12 | 2009-07-06 | Aventis Pharma Limited | Spôsob prípravy imidazolového derivátu |
| KR19990001101A (ko) | 1997-06-12 | 1999-01-15 | 손경식 | 캐테콜 아미노산 유도체, 이의 제조방법 및 그를 함유한 약제 조성물 |
| JP2002504909A (ja) | 1997-06-13 | 2002-02-12 | スミスクライン・ビーチャム・コーポレイション | 新規な置換ピラゾールおよびピラゾリン化合物 |
| JPH119269A (ja) | 1997-06-19 | 1999-01-19 | Kaken Pharmaceut Co Ltd | 破骨細胞系細胞 |
| GB9713732D0 (en) | 1997-06-27 | 1997-09-03 | Pharmacia & Upjohn Spa | Substituted triazinic compounds |
| GB9713733D0 (en) | 1997-06-27 | 1997-09-03 | Pharmacia & Upjohn Spa | Poly-branched polycarboxamido compounds |
| IL133766A0 (en) | 1997-06-30 | 2001-04-30 | Ortho Mcneil Pharm Inc | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
| US6235787B1 (en) | 1997-06-30 | 2001-05-22 | Hoffmann-La Roche Inc. | Hydrazine derivatives |
| GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
| US5843721A (en) | 1997-07-03 | 1998-12-01 | Tularik Inc. | Nucleic acids encoding human NIK protein |
| US6277981B1 (en) | 1997-07-03 | 2001-08-21 | Thomas Jefferson University | Method for design and selection of efficacious antisense oligonucleotides |
| AU8858398A (en) | 1997-07-10 | 1999-02-08 | Pharmacia & Upjohn S.P.A. | Matrix metalloproteinase inhibitors |
| DE19731521A1 (de) | 1997-07-23 | 1999-01-28 | Byk Gulden Lomberg Chem Fab | Budipin bei der Behandlung entzündlicher Erkrankungen des Nervensystems |
| FR2766822B1 (fr) | 1997-07-30 | 2001-02-23 | Adir | Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AR016551A1 (es) | 1997-07-30 | 2001-07-25 | Smithkline Beecham Corp | Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos |
| BR9815895A (pt) | 1997-07-31 | 2001-01-16 | Celgene Corp | Substituido ácido alcanohidroxamico e método para reduzir nìveis de tnf alfa |
| DE69837268D1 (de) | 1997-08-04 | 2007-04-19 | Millennium Pharm Inc | Neue moleküle aus der familie der tango-77-ähnlichen proteine und ihre verewendungen. |
| WO1999006410A1 (en) | 1997-08-04 | 1999-02-11 | Amgen Inc. | Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors |
| KR20000068711A (ko) | 1997-08-06 | 2000-11-25 | 도리이 신이치로 | Ⅳ형 포스포디에스테라제 억제제로서의 1-아릴-1,8-나프틸리딘-4-온 유도체 |
| WO1999007679A1 (en) | 1997-08-08 | 1999-02-18 | Chiroscience Limited | Peptidyl compounds having mmp and tnf inhibitory activity |
| ES2176913T3 (es) | 1997-08-08 | 2002-12-01 | Pfizer Prod Inc | Derivados de acidos arilsulfonilaminohidroxamicos. |
| IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| US5994396A (en) | 1997-08-18 | 1999-11-30 | Centaur Pharmaceuticals, Inc. | Furansulfonic acid derivatives and pharmaceutical compositions containing the same |
| AU8747998A (en) | 1997-08-21 | 1999-03-16 | Takeda Chemical Industries Ltd. | Anti-inflammatory agent |
| JPH11139994A (ja) | 1997-10-31 | 1999-05-25 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| CA2308438A1 (en) | 1997-11-03 | 1999-05-14 | The Wistar Institute Of Anatomy And Biology | Method and compositions for inhibiting angiogenesis and treating cancer |
| US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| WO1999029865A2 (en) | 1997-12-12 | 1999-06-17 | The Rockefeller University | A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof |
| EP1047683A1 (en) | 1998-01-16 | 2000-11-02 | Centaur Pharmaceuticals, Inc. | Thioether furan nitrone compounds |
| ES2193589T3 (es) | 1998-01-20 | 2003-11-01 | Warner Lambert Co | Aldehido del acido n-(2-(5-benciloxicarbonil-amino-6-oxo-2-(4-fluorofenil)-1,6-dihidro-1-pirimidinil)acetoxil)-l-aspartico como un inhibidor (in vivo) del enzima de conversion de la interleucina-1beta. |
| IL137037A0 (en) | 1998-01-23 | 2001-06-14 | Immunex Corp | Acpl dna and polypeptides |
| CA2318482C (en) | 1998-01-23 | 2010-04-13 | Immunex Corporation | Il-18 receptors |
| JP2002528046A (ja) | 1998-01-27 | 2002-09-03 | ミレニアム・フアーマシユーチカルズ・インコーポレーテツド | 新規レセプタースーパーファミリー分子およびそれについての用途 |
| PL342045A1 (en) | 1998-01-27 | 2001-05-21 | American Cyanamid Co | 2,3,4,5-tetrahydro-1h-[1,4]-benzdiazepin-3-hydroxamic acids as inhibitors of matrix metaloproteinases |
| DE69925581T2 (de) | 1998-03-09 | 2006-04-27 | Vertex Pharmaceuticals Inc., Cambridge | 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms |
| DE69925268T2 (de) | 1998-03-16 | 2006-03-23 | Cytovia, Inc., San Diego | Dipeptid-Caspase-Inhibitoren und deren Verwendung |
| ID27002A (id) | 1998-03-19 | 2001-02-22 | Vertex Pharma | Penghambat-penghambat kaspase |
| IL126024A0 (en) | 1998-03-19 | 1999-05-09 | Yeda Res & Dev | Modulators of the function of receptors of the tnf/ngf receptor family and other proteins |
| HUP0003274A2 (hu) | 1998-03-20 | 2001-05-28 | Suntory Limited | Fenil-metil-benzokinon-származékok, és ezeket a vegyületeket tartalmazó NF-kB inhibitor hatású gyógyszerkészítmények |
| JPH11266872A (ja) | 1998-03-20 | 1999-10-05 | Suntory Ltd | ＮＦ−κＢの活性化を抑制する物質のスクリーニング方法 |
| CN1305846C (zh) | 1998-03-26 | 2007-03-21 | 参天制药株式会社 | 脲衍生物 |
| PT2009025E (pt) | 1998-05-14 | 2011-09-19 | Immunex Corp | Método de inibição da actividade dos osteoclastos |
| HUP0102782A3 (en) | 1998-06-19 | 2002-12-28 | Smithkline Beecham Corp | Salycilanilide as inhibitors of transcription factor nf-kb |
| HUP0102492A2 (hu) | 1998-06-19 | 2001-11-28 | Smithkline Beecham Corp. | Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására |
| CA2276216A1 (en) | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
| US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
| KR100537558B1 (ko) | 1998-09-01 | 2005-12-19 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | 인터류킨-18 결합 단백질 |
| NZ510508A (en) | 1998-09-15 | 2005-05-27 | Pharmexa As | Method for down-regulating osteoprotegerin ligand (OPGL) by enabling the production of antibodies against OPGL to treat osteoporosis |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| CZ303703B6 (cs) * | 1998-12-23 | 2013-03-20 | Pfizer Inc. | Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj |
| NZ583002A (en) | 1999-02-03 | 2011-12-22 | Amgen Inc | Novel polypeptide B7RP-1 T cell ligand-receptor pair involved in immune response modulation |
| AU2880400A (en) | 1999-02-12 | 2000-08-29 | Amgen, Inc. | Tnf-related proteins |
| AUPQ314799A0 (en) | 1999-09-29 | 1999-10-21 | University Of Western Australia, The | Bone cell factor |
| MXPA02006027A (es) | 1999-12-16 | 2002-12-05 | Amgen Inc | Moleculas tipo osteoprotegerina/receptor del factor de necrosis de tumor y usos de las mismas. |
| EP1254227A2 (en) | 2000-02-11 | 2002-11-06 | Amgen Inc. | Fusion receptor from tnf family |
| US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| JP4401613B2 (ja) † | 2000-02-23 | 2010-01-20 | アムジエン・インコーポレーテツド | オステオプロテゲリン結合タンパク質のアンタゴニスト性選択的結合因子 |
| JP2003533187A (ja) | 2000-05-03 | 2003-11-11 | アムジエン・インコーポレーテツド | 治療薬としてのＦｃドメインを含む修飾ペプチド |
| US7102050B1 (en) | 2000-05-04 | 2006-09-05 | Exxonmobil Chemical Patents Inc. | Multiple riser reactor |
| US20030215450A1 (en) * | 2000-05-26 | 2003-11-20 | Blake Simon M | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| US7405734B2 (en) * | 2000-07-18 | 2008-07-29 | Silicon Graphics, Inc. | Method and system for presenting three-dimensional computer graphics images using multiple graphics processing units |
| DE10039710B4 (de) | 2000-08-14 | 2017-06-22 | United Monolithic Semiconductors Gmbh | Verfahren zur Herstellung passiver Bauelemente auf einem Halbleitersubstrat |
| AU2001286586A1 (en) * | 2000-08-18 | 2002-03-04 | University Of Massachusetts Medical Center | Trance regulation of chondrocyte differentiation |
| WO2002015846A2 (en) | 2000-08-21 | 2002-02-28 | Smithkline Beecham Corporation | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| DE60129254T2 (de) | 2000-09-22 | 2008-03-13 | Immunex Corp., Thousand Oaks | Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b |
| ZA200305995B (en) * | 2001-01-05 | 2004-08-04 | Pfizer | Antibodies to insulin-like growth factor I receptor. |
| EP1399175A4 (en) | 2001-05-17 | 2005-11-30 | Immunex Corp | THERAPEUTIC USE OF RANK ANTAGONISTS |
| MXPA03011270A (es) | 2001-06-06 | 2004-03-18 | Immunex Corp | Uso de antagonistas rank para tratar cancer. |
| PH12012502439A1 (en) | 2001-06-26 | 2013-06-17 | Amgen Inc | Antibodies to opgl |
| JP4761710B2 (ja) | 2002-04-05 | 2011-08-31 | アムジェン インコーポレイテッド | 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体 |
| JP5782185B2 (ja) | 2012-06-01 | 2015-09-24 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2002
- 2002-06-25 PH PH1/2012/502439A patent/PH12012502439A1/en unknown
- 2002-06-25 YU YU103003A patent/YU103003A/sh unknown
- 2002-06-25 CA CA2451955A patent/CA2451955C/en not_active Expired - Lifetime
- 2002-06-25 CN CNA028166809A patent/CN1547486A/zh active Pending
- 2002-06-25 MX MXPA04000134A patent/MXPA04000134A/es active IP Right Grant
- 2002-06-25 JP JP2003509075A patent/JP4212470B2/ja not_active Expired - Lifetime
- 2002-06-25 SG SG2011076551A patent/SG2011076551A/en unknown
- 2002-06-25 AT AT02749660T patent/ATE464068T1/de active
- 2002-06-25 PL PL371915A patent/PL222211B1/pl unknown
- 2002-06-25 DK DK02749660.3T patent/DK1409016T4/da active
- 2002-06-25 NZ NZ616594A patent/NZ616594A/en not_active IP Right Cessation
- 2002-06-25 ES ES10181323.6T patent/ES2674888T3/es not_active Expired - Lifetime
- 2002-06-25 EP EP10185344.8A patent/EP2295081B1/en not_active Expired - Lifetime
- 2002-06-25 ES ES10185344T patent/ES2706902T3/es not_active Expired - Lifetime
- 2002-06-25 EP EP02749660.3A patent/EP1409016B9/en not_active Expired - Lifetime
- 2002-06-25 TR TR2019/00581T patent/TR201900581T4/tr unknown
- 2002-06-25 ES ES18202340T patent/ES2907826T3/es not_active Expired - Lifetime
- 2002-06-25 EP EP18202340.8A patent/EP3492100B1/en not_active Expired - Lifetime
- 2002-06-25 BR BRPI0210579-9 patent/BRPI0210579B8/pt not_active IP Right Cessation
- 2002-06-25 TR TR2018/09008T patent/TR201809008T4/tr unknown
- 2002-06-25 PT PT10185344T patent/PT2295081T/pt unknown
- 2002-06-25 IL IL15951202A patent/IL159512A0/xx unknown
- 2002-06-25 TR TR2018/09678T patent/TR201809678T4/tr unknown
- 2002-06-25 WO PCT/US2002/020181 patent/WO2003002713A2/en not_active Ceased
- 2002-06-25 ES ES02749660T patent/ES2342820T5/es not_active Expired - Lifetime
- 2002-06-25 EP EP09156995.4A patent/EP2087908B1/en not_active Expired - Lifetime
- 2002-06-25 DK DK10181323.6T patent/DK2270052T3/en active
- 2002-06-25 SG SG2005081195A patent/SG173211A1/en unknown
- 2002-06-25 CN CN201310052370.5A patent/CN103232539B/zh not_active Expired - Lifetime
- 2002-06-25 RS RS20120347A patent/RS54274B1/sr unknown
- 2002-06-25 DK DK09156995.4T patent/DK2087908T3/en active
- 2002-06-25 ME MEP-326/08A patent/MEP32608A/xx unknown
- 2002-06-25 US US10/180,648 patent/US7364736B2/en not_active Expired - Lifetime
- 2002-06-25 DE DE60235989T patent/DE60235989D1/de not_active Expired - Lifetime
- 2002-06-25 EP EP10181323.6A patent/EP2270052B8/en not_active Expired - Lifetime
- 2002-06-25 KR KR1020107002067A patent/KR101038585B1/ko not_active Expired - Lifetime
- 2002-06-25 DK DK10185344.8T patent/DK2295081T3/en active
- 2002-06-25 NZ NZ530765A patent/NZ530765A/en not_active IP Right Cessation
- 2002-06-25 PT PT02749660T patent/PT1409016E/pt unknown
- 2002-06-25 PH PH1/2012/502440A patent/PH12012502440A1/en unknown
- 2002-06-25 MY MYPI20022368A patent/MY143582A/en unknown
- 2002-06-25 ES ES09156995.4T patent/ES2675735T3/es not_active Expired - Lifetime
- 2002-06-25 AU AU2002320157A patent/AU2002320157C1/en not_active Expired
- 2002-06-25 ME MEP-2008-326A patent/ME00232B/me unknown
- 2002-06-25 NZ NZ547695A patent/NZ547695A/en not_active IP Right Cessation
- 2002-06-25 PT PT91569954T patent/PT2087908T/pt unknown
- 2002-06-25 SG SG10201603108QA patent/SG10201603108QA/en unknown
- 2002-06-25 DE DE122010000047C patent/DE122010000047I1/de active Pending
- 2002-06-25 KR KR10-2003-7017009A patent/KR20040023630A/ko not_active Ceased
- 2002-06-25 PT PT101813236T patent/PT2270052T/pt unknown
- 2002-06-25 EA EA200400063A patent/EA021242B9/ru active Protection Beyond IP Right Term
- 2002-06-25 NO NO20200535A patent/NO345566B1/no not_active IP Right Cessation
- 2002-06-26 AR ARP020102401A patent/AR034637A1/es active IP Right Grant
- 2002-06-26 TW TW095103780A patent/TWI326285B/zh not_active IP Right Cessation
- 2002-06-26 TW TW091114055A patent/TWI276443B/zh not_active IP Right Cessation
-
2003
- 2003-12-22 IL IL159512A patent/IL159512A/en active IP Right Grant
-
2004
- 2004-01-23 ZA ZA200400521A patent/ZA200400521B/xx unknown
- 2004-03-10 NO NO20041018A patent/NO343687B1/no not_active IP Right Cessation
-
2005
- 2005-06-25 NZ NZ581637A patent/NZ581637A/en not_active IP Right Cessation
-
2007
- 2007-10-30 US US11/981,664 patent/US8058418B2/en not_active Expired - Lifetime
-
2008
- 2008-07-04 JP JP2008175541A patent/JP4358282B2/ja not_active Expired - Lifetime
- 2008-12-19 AU AU2008261137A patent/AU2008261137C1/en not_active Expired
-
2009
- 2009-07-08 JP JP2009161406A patent/JP4927910B2/ja not_active Expired - Lifetime
-
2010
- 2010-07-08 CY CY20101100637T patent/CY1110196T1/el unknown
- 2010-11-24 CY CY2010016C patent/CY2010016I2/el unknown
- 2010-11-24 LU LU91757C patent/LU91757I2/fr unknown
- 2010-11-25 FR FR10C0050C patent/FR10C0050I2/fr active Active
-
2011
- 2011-11-14 US US13/296,201 patent/US8409578B2/en not_active Expired - Fee Related
-
2012
- 2012-01-17 JP JP2012006740A patent/JP5065529B2/ja not_active Expired - Lifetime
- 2012-03-23 JP JP2012066632A patent/JP2012153701A/ja not_active Withdrawn
- 2012-07-02 JP JP2012148656A patent/JP5576903B2/ja not_active Expired - Lifetime
-
2013
- 2013-03-14 US US13/831,099 patent/US20140134157A1/en not_active Abandoned
-
2014
- 2014-10-19 IL IL235116A patent/IL235116A0/en unknown
- 2014-10-28 JP JP2014218929A patent/JP2015057408A/ja active Pending
- 2014-11-27 JP JP2014239576A patent/JP2015078205A/ja active Pending
-
2015
- 2015-02-12 US US14/621,072 patent/US20150266952A1/en not_active Abandoned
-
2016
- 2016-06-07 JP JP2016113389A patent/JP2016216464A/ja active Pending
- 2016-09-02 US US15/256,194 patent/US20170183417A1/en not_active Abandoned
-
2017
- 2017-12-25 JP JP2017247287A patent/JP2018154614A/ja not_active Ceased
-
2018
- 2018-06-26 CY CY181100655T patent/CY1120656T1/el unknown
- 2018-07-17 CY CY181100747T patent/CY1120658T1/el unknown
-
2019
- 2019-01-21 CY CY20191100079T patent/CY1121151T1/el unknown
- 2019-04-04 NO NO20190456A patent/NO344842B1/no not_active IP Right Cessation
- 2019-06-10 JP JP2019107837A patent/JP2019214563A/ja active Pending
- 2019-11-05 NO NO2019039C patent/NO2019039I1/no unknown
- 2019-12-20 NO NO2019048C patent/NO2019048I1/no unknown
- 2019-12-24 JP JP2019232389A patent/JP2020073518A/ja active Pending
-
2020
- 2020-01-09 US US16/738,751 patent/US20200131271A1/en not_active Abandoned
- 2020-06-18 US US16/905,089 patent/US20200354464A1/en not_active Abandoned
-
2021
- 2021-08-05 JP JP2021128771A patent/JP2022000424A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2010016I2 (el) | Αντισωματα σε μοριο προσδεσης της οστεοπροτεγερινης (opgl) | |
| NO20044347L (no) | Anti-alfavbeta6-antistoff | |
| DE602004022855D1 (de) | Interleukin-10-antikörper | |
| EP1616881A4 (en) | ANTI-MPL ANTIBODY | |
| DK1599504T3 (da) | Modificeret antistof | |
| DE60208635D1 (de) | Navigationssystem | |
| DK1501427T3 (da) | Prøvetagningsmodul | |
| DE60222658D1 (de) | Monoklonaler anti-cd-40-antikörper | |
| EP1396500A4 (en) | ANTI-TRAIL-R ANTIBODIES | |
| DE60234408D1 (de) | Navigationssystem | |
| DE60222968D1 (de) | Navigationsgerät | |
| DK1501856T3 (da) | Anti-HER2 antistofvarianter | |
| DE602004021980D1 (de) | Navigationssystem | |
| DE60200122D1 (de) | Optisches Navigationssystem | |
| DK1543038T4 (da) | Proteinoprensning | |
| DE50200444D1 (de) | Saugmodul | |
| DE602004009744D1 (de) | Reagenzbehälter | |
| DK1653844T3 (da) | Prionspecifikke peptidreagenser | |
| DE60231685D1 (de) | Navigationsvorrichtung | |
| EP1499352A4 (en) | ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES | |
| EP1699487A4 (en) | NEW ANTI-DC-SIGN ANTIBODIES | |
| DE60120514D1 (de) | Plektrum | |
| EE200300569A (et) | CD44v6-spetsiifilised antikehad | |
| DE60216013D1 (de) | Navigationssystem | |
| EP1598368A4 (en) | ANTI-PCI neutralizing ANTIBODY |